drugset / Trial / NCT06607549

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

NCT06607549

Phase 1 Recruiting 12 enrolled University of Utah ADC Therapeutics S.A. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.

Timeline

Start
2025-03-18
Primary completion
2029-11
Completion
2030-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Loncastuximab Tesirine Other / unclassified Intravenous
Subject Rituximab Monoclonal antibody Intravenous